BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
about
Recurrent Glioblastoma: Where we standNonsurgical treatment of recurrent glioblastomaNMR structure of an ethylene interstrand cross-linked DNA which mimics the lesion formed by 1,3-bis(2-chloroethyl)-1-nitrosoureaProcarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.Carmustine induces platelet apoptosis.TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiformeThe future of high-grade glioma: Where we are and where are we going.Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.Standards of care for treatment of recurrent glioblastoma--are we there yet?Glioblastoma multiforme of the optic chiasm: A rare case of common pathology.Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience.High-grade glioma in elderly patients: can the oncogeriatrician help?Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma.The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Nitrosoureas in the Management of Malignant Gliomas.Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes.Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic compaAnti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.Re-do craniotomy for recurrent glioblastoma.PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma.Genetic Strategies for HIV Treatment and Prevention
P2860
Q26765042-3964E494-5144-4E6C-ADA5-51C942D1DA06Q26795560-BB9BE4BA-DF3F-40F1-AB2A-CCD30B38C26EQ27690740-9A660359-539D-44E7-9826-7416A0E51E8EQ33402044-81F6A0E6-9DCF-443F-A5F4-CED123C2E0B8Q33416060-069EC7B6-550B-434D-83BA-7EFE7E1F2A57Q33653031-FBFA2E2B-F617-4423-B60C-1F4F19F77563Q35027024-620B7149-9841-4EE0-90E9-81EF009162DBQ35114090-15F2BE35-501C-4316-902B-D303E7732E9EQ35676452-5265CE45-E449-41C8-8C7E-757C3B439E58Q35733207-8A4FF110-EA77-4926-A677-E9EFAACC5F74Q35920319-3FFAA8E5-B05F-44AD-B7D1-F6CD61484F38Q36143344-904BB084-A184-4B29-AB41-C5623EE657E0Q36500401-6D9C10F0-E32B-4741-8139-88C77E8D6587Q37126125-A1FEF526-06B5-45C8-9EB0-03E2183CB2D4Q37366417-338470B9-51F7-4522-9E9C-63B209ACD15DQ37388217-30CDD7DC-4DA8-43B7-9F27-917A61AD598DQ37592456-6007C7C0-A366-4B2F-85D2-64902B995B88Q37699429-8CC1C262-DA72-4F11-86DD-D6C04EACA1F9Q37712185-40339056-241A-4633-943B-4B1AED2F0259Q38179019-B9D87FA1-9D98-4F90-8448-75E277C19809Q38205133-B02F22E8-DD5B-48DA-A128-FDA06193CAC0Q38691732-2A4AF1EC-963C-4BF0-91A5-84A84892923CQ38938545-A37AA3D6-15B5-4D5D-9937-DFCB2FEEAE2FQ47145292-4F09B0C9-FC4D-4EAF-B2D1-F4D13C908026Q47161862-80B1F8FC-6DDE-4B30-861C-63AACBFB6D6DQ48282362-46857A75-F900-4FDB-AD04-EBFE3484A54DQ55139727-C1C416E5-9317-4E4A-B879-1BE13ECE31E5Q58604627-2B9DDFA0-B60B-4DAA-89BC-95DD3F8C0C6E
P2860
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@ast
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@en
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@nl
type
label
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@ast
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@en
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@nl
prefLabel
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@ast
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@en
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@nl
P2093
P2860
P356
P1433
P1476
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
@en
P2093
Guido Nikkhah
Marcus O Pinsker
Michael Trippel
Thomas Reithmeier
Tobias Piroth
P2860
P2888
P356
10.1186/1471-2407-10-30
P407
P50
P577
2010-02-02T00:00:00Z
P5875
P6179
1032249425